Print Page | Close Page

 
 

Circio

Address: Pb. 6887 St. Olavs plass, Oslo, NO-0130
 
Country: Norway
 
Sectors: Collaborations & Partnerships- R&D, Collaborations & Partnerships-Licensing
 
Website: https://www.circio.com/en
 
- - -
 

About Us

Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.

 
- - -
 

Sectors

  • Collaborations & Partnerships- R&D
 
  • Collaborations & Partnerships-Licensing
 
- - -
 

Categories

  • Biologics
  • Biotechnology
  • Gene Therapy
  • Gene Therapy Products
  • Drug Discovery Services
  • Clinical Development-Pipeline
  • RNA based Products
 
  • RNA-Circular
  • Immunotherapy
  • immuno-oncology
  • Oncology Products
  • Anti-Cancer Products
  • Messenger RNA
  • Platform Technology-Drug Discovery
 
- - -
 

News

 
24th January 2025
 

4basebio partners with Circio to build and test circVec synthetic DNA vectors for genetic medicine and vaccines

 

Oslo, Norway 21 January 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces that it has entered a partnership with 4basebio PLC of Cambridge, UK, for joint development and in vivo delivery testing of synthetic circVec DNA vectors.  


“The circVec technology achieves up to 70 times prolonged RNA half-life and 15-fold increase in protein levels vs. standard mRNA-based expression in vivo using plasmid DNA,” said Dr. Thomas Hansen, CTO of Circio. “We have therefore now partnered with 4basebio, a world-leader in next-generation DNA vectors for therapeutic applications. Combining 4basebio´s vector and delivery expertise with Circio´s circVec powerful expression technology has the potential to create a durable, repeat-dosable, non-viral platform for future synthetic DNA gene therapies.”

 
-
 
 
13th May 2024
 

Circio presents pre-clinical proof-of-concept data for its circVec gene therapy platform at the ASGCT 2024 meeting

 

Oslo, Norway, 13 May 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing circular RNA-based gene therapy, today announces that it has presented two posters that demonstrate in vivo proof-of-concept for its powerful and differentiated circVec platform approach to gene therapy. The two posters were presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting 7-11 May in Baltimore, USA

 
- - -
 
Printed: 16-Mar-2026 at 06:52:21 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com